Managing adverse effects of immunotherapy

James N. Gerson, Chethan Ramamurthy, Hossein Borghaei

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Remarkable efficacy has been achieved in a variety of cancer types by targeting immune checkpoints. The cytotoxic T-lymphocyte–associated antigen 4 inhibitor ipilimumab, the programmed death 1 inhibitors nivolumab and pembrolizumab, and the programmed death ligand 1 inhibitors atezolizumab, avelumab, and durvalumab are the agents currently approved by the US Food and Drug Administration for the treatment of certain advanced malignancies. These agents mark a departure from both standard cytotoxic chemotherapy and targeted therapy. However, they are associated with a unique set of immune-related adverse events (irAEs), which can manifest as a wide range of autoimmune phenomena. The irAEs can affect any system in the body and in rare cases are life-threatening. It is critical for the practicing medical oncologist to recognize and promptly treat any irAEs that may develop.

Original languageEnglish (US)
Pages (from-to)364-374
Number of pages11
JournalClinical Advances in Hematology and Oncology
Volume16
Issue number5
StatePublished - May 2018
Externally publishedYes

Keywords

  • Immune-related adverse events (irAEs)
  • Immunotherapy
  • Programmed death 1 (PD-1)
  • Programmed death ligand 1 (PD-L1)

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Managing adverse effects of immunotherapy'. Together they form a unique fingerprint.

Cite this